Advaxis Inc (ADXS) 23.34 $ADXS
Health of Health Care Stocks: Complementary Research on Enzon Pharmaceuticals, Durect Corporation, Vertex Pharmaceuticals, Advaxis, and Omnicare
PR Newswire - Fri Apr 24, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENZN: 1.72 (+0.18), OCR: 86.11 (-0.20), ADXS: 23.34 (-0.27), VRTX: 133.20 (-2.62), DRRX: 2.11 (-0.46)
Interesting ADXS Put And Call Options For June 19th
StockOptionsChannel.com - Wed Apr 22, 10:37AM CDT
Investors in Advaxis, Inc. saw new options begin trading this week, for the June 19th expiration.
ADXS: 23.34 (-0.27)
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 7.12 (+0.75), ADXS: 23.34 (-0.27), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), BMY: 65.80 (-0.20), FPRX: 24.20 (-0.26)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TTS: 14.01 (-0.17), FATE: 5.91 (-0.24), HAS: 71.61 (-0.10), ADXS: 23.34 (-0.27), AMSC: 6.88 (-3.12), ECHO: 32.68 (-1.14), LJPC: 22.95 (-1.39), RMBS: 13.99 (-0.31), TGLS: 11.72 (-0.08), VLTC: 11.54 (+0.50), FTNT: 38.68 (-0.04)
Why Advaxis, Inc. Shares Lifted Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 21, 4:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Advaxis , a clinical-stage biotech company...
ADXS: 23.34 (-0.27)
Advaxis Presents Lm-LLO Cancer Immunotherapy Data at the 2015 American Association for Cancer Research Meeting
GlobeNewswire - Tue Apr 21, 12:00PM CDT
ADXS-HPV Combined with Anti-OX40 or Anti-GITR Antibodies Demonstrates Tumor Growth Inhibition and Prolonged Survival in a Preclinical Study
ADXS: 23.34 (-0.27)
Advaxis files to sell up to $200M in stock; shares -6%
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 5:11PM CDT
ADXS: 23.34 (-0.27)
Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles In Value On IPO Debut
at The Street - Wed Apr 15, 10:35AM CDT
Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.
ADXS: 23.34 (-0.27), ADRO: 36.00 (-0.39)
Advaxis Shares Rise Ahead of Aduro's Rival Cancer Immunotherapy IPO
at The Street - Tue Apr 14, 7:43AM CDT
Advaxis' market value is half as large as competitor Aduro Biotech, which is expected to price its initial public offering on Thursday.
JNJ: 101.08 (+0.62), ADXS: 23.34 (-0.27), ADRO: 36.00 (-0.39), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), BMY: 65.80 (-0.20), NVS: 104.28 (-1.22)
'Mad Money' Lightning Round: I Like Phillips 66, Don't Sell It
at The Street - Tue Apr 14, 5:00AM CDT
Cramer is not a big believer in Sturm Ruger, likes Kohlberg Kravis Roberts but is avoiding Emerge Energy Services.
PSX: 81.59 (+0.36), ADXS: 23.34 (-0.27), BX: 41.41 (+0.42), EMES: 44.65 (-5.95), NOC: 161.78 (-1.05), TGTX: 16.23 (-0.18), SFL: 15.63 (-0.01), FRT: 140.42 (+0.15), KKR: 23.39 (-0.15), O: 49.37 (-0.02), VTR: 72.82 (-0.24), EOG: 96.72 (-1.55), RGR: 56.18 (-0.03), STO: 19.88 (+0.02)
Be Careful Of The Sand Fracking Business - Cramer's Lightning Round (4/13/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Apr 14, 4:44AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 13. Bullish Calls: TG Therapeutics (NASDAQ: TGTX ): "Why don't we buy more? I thought Mike Weiss was very convincing when we had him on. I...
PSX: 81.59 (+0.36), ZIOP: 10.81 (-0.39), ADXS: 23.34 (-0.27), LMT: 195.37 (-1.83), BX: 41.41 (+0.42), EMES: 44.65 (-5.95), NOC: 161.78 (-1.05), TGTX: 16.23 (-0.18), SFL: 15.63 (-0.01), FRT: 140.42 (+0.15), KKR: 23.39 (-0.15), O: 49.37 (-0.02), VTR: 72.82 (-0.24), PBR: 9.99 (+0.59), RDS.B: 63.67 (-0.07), RDS.A: 62.76 (-0.20), EOG: 96.72 (-1.55), RCPT: 169.88 (-1.26), NAO: 9.77 (-0.26), OA: 72.91 (-1.33), RGR: 56.18 (-0.03), UNP: 107.51 (-0.61), STO: 19.88 (+0.02)
Jim Cramer's 'Mad Money' Recap: Don't Leave Gains on the Table
at The Street - Mon Apr 13, 7:19PM CDT
Using traditional analysis, investors might think Netflix is ridiculously expensive compared to where shares traded just a few months or years ago. They'd be wrong, Cramer says.
EMES: 44.65 (-5.95), BX: 41.41 (+0.42), AWAY: 27.18 (-4.99), NOC: 161.78 (-1.05), SFL: 15.63 (-0.01), KKR: 23.39 (-0.15), O: 49.37 (-0.02), VTR: 72.82 (-0.24), CTXS: 66.99 (-0.35), INFA: 48.16 (+0.16), EOG: 96.72 (-1.55), RCPT: 169.88 (-1.26), TWTR: 50.82 (-0.59), RGR: 56.18 (-0.03), CSCO: 28.82 (+0.15), PSX: 81.59 (+0.36), ADXS: 23.34 (-0.27), TGTX: 16.23 (-0.18), DISCA: 32.71 (-0.93), FRT: 140.42 (+0.15), NFLX: 558.40 (-0.66), PSG: 20.40 (-0.03), BLKB: 50.30 (-0.17), RVBD: 20.99 (-0.01), RHT: 76.83 (-0.02), STO: 19.88 (+0.02), CBS: 62.72 (+1.09)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 401.71 (-28.57), SPHS: 0.80 (-0.03), ADMS: 17.70 (-0.03), TKMR: 18.75 (-0.25), CBYL: 7.45 (-0.11), HPTX: 45.97 (-0.11), QURE: 26.09 (-0.28), SHPG: 255.11 (-0.26), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), ABBV: 66.07 (+1.82), CBMG: 29.51 (-1.85), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), ADXS: 23.34 (-0.27), PTLA: 38.51 (-0.85), BMY: 65.80 (-0.20), OCUL: 25.36 (-1.12), NVO: 56.65 (+0.44), DVA: 83.91 (+0.50), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ALXN: 180.08 (-4.50), NVS: 104.28 (-1.22)
Advaxis Included Among "25 Top Immunotherapy Companies" in Newly Launched Loncar Cancer Immunotherapy Index (LCINDX)
GlobeNewswire - Fri Apr 10, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its stock has been added to the Loncar Cancer Immunotherapy Index (LCINDX). Based on current allocations and current share prices, Advaxis is the most heavily weighted stock in LCINDX.
ADXS: 23.34 (-0.27)
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 6.89 (-0.71), BIIB: 401.71 (-28.57), NWBO: 8.47 (-0.15), ADXS: 23.34 (-0.27), ADRO: 36.00 (-0.39), AMGN: 167.91 (-1.26), GSK: 46.59 (+0.28), ONTY: 1.74 (-0.05), IMUC: 0.53 (-0.01), MACK: 13.42 (-0.25), GBIM: 8.19 (-0.23), ARGS: 8.56 (-0.18), BLCM: 27.88 (-0.46), NLNK: 52.10 (-0.90)
Why Advaxis Inc. Shares Soared Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 08, 3:50PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Advaxis Inc . jumped by 17%...
ADXS: 23.34 (-0.27), MRK: 57.60 (+0.09)
Health of Health Care Stocks: Complementary Research on Enzon Pharmaceuticals, Durect Corporation, Vertex Pharmaceuticals, Advaxis, and Omnicare
PR Newswire - Fri Apr 24, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENZN: 1.72 (+0.18), OCR: 86.11 (-0.20), ADXS: 23.34 (-0.27), VRTX: 133.20 (-2.62), DRRX: 2.11 (-0.46)
Interesting ADXS Put And Call Options For June 19th
StockOptionsChannel.com - Wed Apr 22, 10:37AM CDT
Investors in Advaxis, Inc. saw new options begin trading this week, for the June 19th expiration.
ADXS: 23.34 (-0.27)
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 7.12 (+0.75), ADXS: 23.34 (-0.27), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), BMY: 65.80 (-0.20), FPRX: 24.20 (-0.26)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TTS: 14.01 (-0.17), FATE: 5.91 (-0.24), HAS: 71.61 (-0.10), ADXS: 23.34 (-0.27), AMSC: 6.88 (-3.12), ECHO: 32.68 (-1.14), LJPC: 22.95 (-1.39), RMBS: 13.99 (-0.31), TGLS: 11.72 (-0.08), VLTC: 11.54 (+0.50), FTNT: 38.68 (-0.04)
Why Advaxis, Inc. Shares Lifted Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 21, 4:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Advaxis , a clinical-stage biotech company...
ADXS: 23.34 (-0.27)
Advaxis Presents Lm-LLO Cancer Immunotherapy Data at the 2015 American Association for Cancer Research Meeting
GlobeNewswire - Tue Apr 21, 12:00PM CDT
ADXS-HPV Combined with Anti-OX40 or Anti-GITR Antibodies Demonstrates Tumor Growth Inhibition and Prolonged Survival in a Preclinical Study
ADXS: 23.34 (-0.27)
Advaxis files to sell up to $200M in stock; shares -6%
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 5:11PM CDT
ADXS: 23.34 (-0.27)
Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles In Value On IPO Debut
at The Street - Wed Apr 15, 10:35AM CDT
Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.
ADXS: 23.34 (-0.27), ADRO: 36.00 (-0.39)
Advaxis Shares Rise Ahead of Aduro's Rival Cancer Immunotherapy IPO
at The Street - Tue Apr 14, 7:43AM CDT
Advaxis' market value is half as large as competitor Aduro Biotech, which is expected to price its initial public offering on Thursday.
JNJ: 101.08 (+0.62), ADXS: 23.34 (-0.27), ADRO: 36.00 (-0.39), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), BMY: 65.80 (-0.20), NVS: 104.28 (-1.22)
'Mad Money' Lightning Round: I Like Phillips 66, Don't Sell It
at The Street - Tue Apr 14, 5:00AM CDT
Cramer is not a big believer in Sturm Ruger, likes Kohlberg Kravis Roberts but is avoiding Emerge Energy Services.
PSX: 81.59 (+0.36), ADXS: 23.34 (-0.27), BX: 41.41 (+0.42), EMES: 44.65 (-5.95), NOC: 161.78 (-1.05), TGTX: 16.23 (-0.18), SFL: 15.63 (-0.01), FRT: 140.42 (+0.15), KKR: 23.39 (-0.15), O: 49.37 (-0.02), VTR: 72.82 (-0.24), EOG: 96.72 (-1.55), RGR: 56.18 (-0.03), STO: 19.88 (+0.02)
Be Careful Of The Sand Fracking Business - Cramer's Lightning Round (4/13/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Apr 14, 4:44AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 13. Bullish Calls: TG Therapeutics (NASDAQ: TGTX ): "Why don't we buy more? I thought Mike Weiss was very convincing when we had him on. I...
PSX: 81.59 (+0.36), ZIOP: 10.81 (-0.39), ADXS: 23.34 (-0.27), LMT: 195.37 (-1.83), BX: 41.41 (+0.42), EMES: 44.65 (-5.95), NOC: 161.78 (-1.05), TGTX: 16.23 (-0.18), SFL: 15.63 (-0.01), FRT: 140.42 (+0.15), KKR: 23.39 (-0.15), O: 49.37 (-0.02), VTR: 72.82 (-0.24), PBR: 9.99 (+0.59), RDS.B: 63.67 (-0.07), RDS.A: 62.76 (-0.20), EOG: 96.72 (-1.55), RCPT: 169.88 (-1.26), NAO: 9.77 (-0.26), OA: 72.91 (-1.33), RGR: 56.18 (-0.03), UNP: 107.51 (-0.61), STO: 19.88 (+0.02)
Jim Cramer's 'Mad Money' Recap: Don't Leave Gains on the Table
at The Street - Mon Apr 13, 7:19PM CDT
Using traditional analysis, investors might think Netflix is ridiculously expensive compared to where shares traded just a few months or years ago. They'd be wrong, Cramer says.
EMES: 44.65 (-5.95), BX: 41.41 (+0.42), AWAY: 27.18 (-4.99), NOC: 161.78 (-1.05), SFL: 15.63 (-0.01), KKR: 23.39 (-0.15), O: 49.37 (-0.02), VTR: 72.82 (-0.24), CTXS: 66.99 (-0.35), INFA: 48.16 (+0.16), EOG: 96.72 (-1.55), RCPT: 169.88 (-1.26), TWTR: 50.82 (-0.59), RGR: 56.18 (-0.03), CSCO: 28.82 (+0.15), PSX: 81.59 (+0.36), ADXS: 23.34 (-0.27), TGTX: 16.23 (-0.18), DISCA: 32.71 (-0.93), FRT: 140.42 (+0.15), NFLX: 558.40 (-0.66), PSG: 20.40 (-0.03), BLKB: 50.30 (-0.17), RVBD: 20.99 (-0.01), RHT: 76.83 (-0.02), STO: 19.88 (+0.02), CBS: 62.72 (+1.09)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 401.71 (-28.57), SPHS: 0.80 (-0.03), ADMS: 17.70 (-0.03), TKMR: 18.75 (-0.25), CBYL: 7.45 (-0.11), HPTX: 45.97 (-0.11), QURE: 26.09 (-0.28), SHPG: 255.11 (-0.26), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), ABBV: 66.07 (+1.82), CBMG: 29.51 (-1.85), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), ADXS: 23.34 (-0.27), PTLA: 38.51 (-0.85), BMY: 65.80 (-0.20), OCUL: 25.36 (-1.12), NVO: 56.65 (+0.44), DVA: 83.91 (+0.50), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ALXN: 180.08 (-4.50), NVS: 104.28 (-1.22)
Advaxis Included Among "25 Top Immunotherapy Companies" in Newly Launched Loncar Cancer Immunotherapy Index (LCINDX)
GlobeNewswire - Fri Apr 10, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its stock has been added to the Loncar Cancer Immunotherapy Index (LCINDX). Based on current allocations and current share prices, Advaxis is the most heavily weighted stock in LCINDX.
ADXS: 23.34 (-0.27)
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 6.89 (-0.71), BIIB: 401.71 (-28.57), NWBO: 8.47 (-0.15), ADXS: 23.34 (-0.27), ADRO: 36.00 (-0.39), AMGN: 167.91 (-1.26), GSK: 46.59 (+0.28), ONTY: 1.74 (-0.05), IMUC: 0.53 (-0.01), MACK: 13.42 (-0.25), GBIM: 8.19 (-0.23), ARGS: 8.56 (-0.18), BLCM: 27.88 (-0.46), NLNK: 52.10 (-0.90)
Why Advaxis Inc. Shares Soared Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 08, 3:50PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Advaxis Inc . jumped by 17%...
ADXS: 23.34 (-0.27), MRK: 57.60 (+0.09)
